CRIS Current Research Information System

PILERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.636
EU - Europa 2.646
AS - Asia 973
AF - Africa 194
SA - Sud America 15
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.474
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.614
GB - Regno Unito 688
SE - Svezia 462
DE - Germania 389
IT - Italia 376
CN - Cina 372
VN - Vietnam 278
IN - India 180
IE - Irlanda 128
UA - Ucraina 123
RU - Federazione Russa 110
FR - Francia 101
BG - Bulgaria 68
SG - Singapore 60
ZA - Sudafrica 60
TG - Togo 54
EE - Estonia 50
CH - Svizzera 40
CI - Costa d'Avorio 40
FI - Finlandia 31
NG - Nigeria 25
JO - Giordania 23
CA - Canada 18
AT - Austria 17
IR - Iran 15
JP - Giappone 12
HR - Croazia 11
BR - Brasile 8
PL - Polonia 8
SC - Seychelles 8
AU - Australia 6
BE - Belgio 6
CZ - Repubblica Ceca 5
ES - Italia 5
LB - Libano 5
DK - Danimarca 4
EG - Egitto 4
MX - Messico 4
RS - Serbia 4
TR - Turchia 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
CL - Cile 3
HK - Hong Kong 3
HU - Ungheria 3
IL - Israele 3
MD - Moldavia 3
PH - Filippine 3
PT - Portogallo 3
RO - Romania 3
AR - Argentina 2
CO - Colombia 2
KE - Kenya 2
KR - Corea 2
LU - Lussemburgo 2
NL - Olanda 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
GR - Grecia 1
KZ - Kazakistan 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 7.474
Salva come PNG Salva come JPEG
Città #
Southend 619
Fairfield 548
Chandler 450
Ashburn 244
Woodbridge 219
Houston 217
Wilmington 215
Seattle 212
Princeton 185
Cambridge 157
Dong Ket 140
Dublin 128
Ann Arbor 102
Westminster 65
Sofia 64
Nanjing 61
Jacksonville 60
Redmond 56
Berlin 54
Bologna 54
Lomé 54
Beijing 53
Singapore 47
Padova 41
Saint Petersburg 41
Abidjan 40
Bremen 39
San Diego 38
Jinan 36
New York 35
Redwood City 30
Helsinki 29
Turin 29
Shenyang 27
Abeokuta 25
Bern 25
Amman 23
Hebei 22
Nanchang 21
Changsha 20
Tianjin 20
Falls Church 19
Milan 18
Mülheim 17
Des Moines 16
Norwalk 16
Vienna 16
Olalla 15
Dearborn 14
Haikou 13
Rome 13
Zhengzhou 13
Hyderabad 12
Jiaxing 12
Hangzhou 11
London 11
Kuban 10
Zola Predosa 10
Taiyuan 9
Boardman 8
Florence 8
Sault Sainte Marie 8
Bühl 7
Council Bluffs 7
Lanzhou 7
Mahé 7
Ravenna 7
Taizhou 7
Zanjan 7
Brussels 6
Frankfurt Am Main 6
Los Angeles 6
Medford 6
Pune 6
São Paulo 6
Tokyo 6
Toronto 6
Catania 5
Gloucester 5
Lausanne 5
Ningbo 5
Paris 5
Verona 5
Belgrade 4
Ferrara 4
Frankfurt am Main 4
Guangzhou 4
Istanbul 4
Pavia 4
San Francisco 4
Warsaw 4
Budapest 3
Buffalo 3
Calderara di Reno 3
Changchun 3
Chicago 3
Clifton 3
Copenhagen 3
Fremont 3
Giza 3
Totale 5.000
Salva come PNG Salva come JPEG
Nome #
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 173
Primary cutaneous large B-cell lymphoma, leg type, localized on the dorsum 151
Annular lesions located on the right forearm. 145
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 134
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 134
Atopic Dermatitis and the Atopic March: What Is New? 130
Anaplastic Large Cell Lymphoma: a critical reappraisal 129
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 128
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 119
BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role 119
Syringotropic mycosis fungoides: a rare variant of the disease with peculiar clinicopathologic features. 117
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 117
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 113
Rosacea-like tinea incognito 113
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS). 111
Photodynamic therapy: An option in mycosis fungoides 111
Chilblain lupus erythematosus in a patient affected by Hodgkin lymphoma 111
Large granular lymphocytic leukaemia mimicking ulcer of the lower limb 110
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 110
An asymptomatic plaque on the chest: A quiz 109
Brownish asymptomatic lesions on the arms and legs 107
Bosentan and Extracorporeal Photochemotherapy in Eosinophilic Fasciitis: Synergistic Action or Fortuitous Coincidence? 106
Atypical piloleiomyoma of the face presenting with central ulceration 104
Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution? 103
Alopecia areata-like mycosis fungoides: Lions for lambs 101
Dermatofibrosarcoma protuberans secondary to a decorative tattoo: An Isotattootopic Response? 101
Merkel cell carcinoma: a prompt diagnosis to increase survival 100
Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktärem Sézary-Syndrom 99
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium 98
Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study 98
Tattoo-associated pseudolymphomatous reaction and its successful treatment with hydroxychloroquine. 97
Herpes zoster in COVID-19-positive patients 95
Vemurafenib mucosal side-effect. 94
Indolent lymphoma: the pathologist's viewpoint 93
Primary cutaneous small/medium-sized pleomorphic T-cell lymphoproliferative disorder shows a common vascular pattern at dermoscopy 92
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 92
Extramedullary metastatic plasmacytoma in a multiple myeloma patient 90
The karma of Kikuchi's disease. 89
Vascular endothelial growth factor A (VEGFA) expression in mycosis fungoides 89
Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukaemia patients 88
Leukemia cutis in a Ph+ ALL patient treated with ponatinib 88
Lymphoma classification: Past, present and future 86
Cutaneous adverse-events in patients treated with Ibrutinib 86
Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab 85
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 84
Peripheral T-cell lymphoma. 83
Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome? 83
Granulomatous tattoo reaction in a nivolumab-treated patient 83
Persistent agmination of lymphomatoid papulosis: an ongoing debate. 83
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model 83
A large mass and erythematous-violaceous plaques - Ein großer tumor und livid-erythematöse plaques 82
Idiopathic follicular mucinosis: Can dermoscopy be helpful? 82
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 79
Verrucous mycosis fungoides. 78
Erythematous induration of the chest 77
The role of myeloid derived suppressor cells in mycosis fungoides 77
Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma 76
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 76
Pityriasis lichenoides getriggert durch eine Masern‐Mumps‐Röteln‐Impfung 74
Papular mycosis fungoides: a new casa expanding the spectrum of phenotypic and clinical findings 72
Chilblain lesions after COVID-19 mRNA vaccine 71
Multiple familial trichodiscomas. 70
Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement 70
Lymphoma classification: the quiet after the storm. 68
null 68
Squamous cell carcinoma developed after ingenol mebutate therapy: A possible consequence of the treatment? 67
Sézary Syndrome without erythroderma featuring a CD30+ progression 67
Management of malignant cutaneous wounds in oncologic patients 66
Mycosis fungoides: disease evolution of the "lion queen" revisited. 61
Unilesional folliculotropic mycosis fungoides: a true rarity in the clinico-pathologic spectrum? 55
Micosi fungoide: nuovi orizzonti dal microambiente? 54
Subacute cutaneous lupus erythematosus induction after SARS-CoV-2 vaccine in a patient with primary biliary cholangitis 54
Pityriasis lichenoides triggered by measles-mumps-rubella vaccine injection 53
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 53
Newly-discovered neural features expand the pathobiological knowledge of blastic plasmacytoid dendritic cell neoplasm 50
Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides 50
The microenvironment’s role in mycosis fungoides and sézary syndrome: From progression to therapeutic implications 50
null 49
Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review 48
Is Dermoscopy Useful for the Diagnosis of Pseudolymphomas? 48
Erosive pustular dermatosis of the leg: An uncommon entity? 47
Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP) 47
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 41
Dimethyl fumarate: a case of improvement of alcoholic steatohepatitis in an elderly psoriatic patient 38
Prognostic significance of Bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal 37
Estimating the incidence of COVID-19 skin manifestations on the general population in a territorial setting 37
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives 34
Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an e-Delphi consensus 32
MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma 32
PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome 30
Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas 19
TOX Expression in Mycosis Fungoides and Sezary Syndrome 16
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 16
Who is the culprit? A toxic epidermal necrolysis case in a patient treated with rituximab plus polatuzumab 15
Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease 15
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome 12
CUTANEOUS B-CELL LYMPHOMAS: UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT 12
A Microenvironment-Related Nine-Gene Signature May Predict Survival in Mycosis Fungoides Patients at Diagnosis 11
Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis? 10
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region 9
Totale 7.719
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.791 266 46 15 109 184 164 220 237 241 126 73 110
2020/20211.223 201 112 39 54 14 75 44 50 128 67 50 389
2021/20221.598 83 45 99 137 148 98 27 137 88 137 337 262
2022/20231.880 208 264 107 247 140 152 69 144 265 63 154 67
2023/2024593 39 109 33 48 35 109 80 44 10 36 18 32
2024/2025108 108 0 0 0 0 0 0 0 0 0 0 0
Totale 7.752